Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis by Brady, Joanne E. et al.
REVIEW Open Access
Risk markers for fatal and non-fatal
prescription drug overdose: a meta-analysis
Joanne E. Brady1*, Rebecca Giglio2, Katherine M. Keyes1,2, Charles DiMaggio3 and Guohua Li1,2,4
Abstract
Background: Drug overdose is a public health crisis in the United States, due in part to the unintended
consequences of increases in prescribing of opioid analgesics. Many clinicians evaluate risk markers for
opioid-related harms when prescribing opioids for chronic pain; however, more data on predictive risk
markers are needed. Risk markers are attributes (modifiable and non-modifiable) that are associated with
increased probability of an outcome. This review aims to identify risk markers associated with fatal and non-fatal
prescription drug overdose by synthesizing findings in the existing peer-reviewed and grey literature. Eligible cohort,
case-control, cross-sectional, and case-cohort studies were reviewed and data were extracted for qualitative and
quantitative synthesis.
Findings: Summary odds ratios (SOR) were estimated from 29 studies for six risk markers: sex, age, race, psychiatric
disorders, substance use disorder (SUD), and urban/rural residence. Heterogeneity was assessed and effect estimates
were stratified by study characteristics. Of the six risk markers identified, SUD had the strongest association with drug
overdose death (SOR = 5.24, 95% confidence interval (CI) = 3.53 - 7.76), followed by psychiatric disorders (SOR = 3.94,
95% CI = 3.09 - 5.01), white race (SOR = 2.28, 95% CI = 1.93 - 2.70), the 35-44 year age group relative to the 25-34 year
reference group (SOR = 1.52, 95% CI = 1.31 - 1.76), and male sex (SOR = 1.33, 95% CI = 1.17 - 1.51).
Conclusions: This review highlights fatal and non-fatal prescription drug risk markers most frequently assessed in
peer-reviewed and grey literature. There is a need to better understand modifiable risk markers and underlying reasons
for drug misuse in order to inform interventions that may prevent future drug overdoses.
Keywords: Accidents, Analgesics, Opioid/toxicity, Drug overdose, Mortality, Prescription drugs/toxicity, Prevalence,
Public health, Risk factors, Substance-related disorder
Review
Unintentional drug poisoning (overdose) is defined by the
Centers for Disease Control and Prevention (CDC) as ac-
cidental harm caused by the ingestion, inhalation, injec-
tion or absorption of a substance that is not intended to
cause harm (Centers for Disease Control and Prevention
2015). Overdose deaths have been increasing for the past
20 years (Warner et al. 2011; Centers for Disease Control
and Prevention 2012; Rudd 2016); prescription drug over-
dose (PDO) deaths have played a considerable role in the
drug overdose epidemic (Centers for Disease Control and
Prevention 2012; Warner et al. 2009; Okie 2010). In-
creases in PDO deaths have coincided with an increase in
nonmedical use of prescription drugs and prescription
drug-related morbidity (Centers for Disease Control
and Prevention 2012; Okie 2010; Centers for Disease
Control and Prevention 2011; Dhalla et al. 2009; Coben
et al. 2010; Cai et al. 2010). The rise in overdose is
largely attributable to greater therapeutic and nonmedi-
cal prescription drug use and abuse, specifically use and
abuse of opioid analgesics (Centers for Disease Control and
Prevention 2015; Centers for Disease Control Prevention
2005; Centers for Disease Control Prevention 2011; Mueller
et al. 2006; Wunsch et al. 2009; Centers for Disease Control
Prevention 2012). These increases have led to numerous
regulatory changes in many states, as well as a new prescrib-
ing guideline to help providers evaluate risk markers for
opioid-related harms when prescribing opioids for chronic
pain (Dowell et al. 2016).
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Risk markers are attributes that are associated with in-
creased probability of an outcome, and may or may not
be modifiable or causal factors (Burt 2001). PDO risk
markers may be important for informing public health
interventions (Keyes et al. 2014; Diez Roux 2004). How-
ever, studies of PDO have not consistently identified the
same risk markers or the same effects (Bohnert et al.
2012; Bohnert et al. 2011; Dunn et al. 2010; Havens et
al. 2011a; Cochella and Bateman 2011; McKenzie and
McFarland 2007; Silva et al. 2013) and there has not
been a systematic evaluation of risk markers associated
with PDO. Extant reviews and studies of PDO and drug-
related mortality have been narrative or have focused on
trends over time, but have not systematically evaluated
the evidence in support of various risk markers (Warner
et al. 2011; Warner et al. 2009; Centers for Disease
Control Prevention 2005; Buckley and McManus 2004;
Crombie and McLoone 1998; Gilchrist et al. 2012;
Bateman et al. 2003; Degenhardt et al. 2001; Fernandez
et al. 2006; Fischer et al. 2006; Green et al. 2011; Hall et
al. 1999; Lynskey and Hall 1998; Paulozzi and Xi 2008;
Paulozzi et al. 2006; Rosca et al. 2012; Romelsjo et al.
2010; Roxburgh et al. 2011; Shah et al. 2005; Shah et al.
2012; Williamson et al. 1997; Wong et al. 2010; Harlow
1991; Lloyd and McElwee 2011; Paulozzi and Stier 2010;
Paulozzi et al. 2012).
This review aims to provide a comprehensive and quan-
titative evaluation of the existing literature concerning the
most frequently examined risk markers associated with
PDO. Six commonly examined risk markers were identi-
fied for further investigation: sex, age, race, comorbid
psychiatric disorder, comorbid substance use disorder
(SUD) and urban/rural area of residence. Understanding
risk markers may help identify modifiable factors which
may be intervened upon, and aid in the identification of
individuals at greatest risk for PDO. This review examines
characteristics of previous research studies, in order to
understand differences in their findings, identify salient
gaps in the PDO literature and ultimately to help inform
policy and guide decision-making regarding preventive in-
terventions to curb PDO.
Methods
Reporting in this meta-analysis followed standard
methodology, adhering to the procedural and reporting
recommendations for conducting meta-analyses outlined
in the PRISMA statement and MOOSE guidelines (Moher
et al. 2009; Stroup et al. 2000).
Eligibility
This review contains two components: 1) a systematic
descriptive review, and 2) a systematic quantitative
meta-analysis. To be included, a study must have been
published in the English language from January 1, 1990
to December 1, 2016. Included studies used a standard
epidemiologic study design (e.g., cohort, case-control,
cross-sectional, case-cohort study or survey) from
which effect measures could be extracted. Publications
reporting on case-series (e.g., medical examiner data
with no non-events and not including rates, compara-
tive case-series, letters, editorials commentaries, opin-
ion pieces), case reports, reviews, time-series or trend
studies were excluded. If two studies examined the
same outcome in the same individuals during the same
time period, but examined a different control series,
only the study published first was included (Lanier et al.
2012; Johnson et al. 2012; Cheng et al. 2013).
In this review, prescription drugs are defined as any
drug requiring a prescription from a licensed healthcare
provider, including controlled and non-controlled sub-
stances. Studies that focus on illegal drugs, excluding
prescription drugs, or that give no indication of prescrip-
tion drug use were excluded. As this review examines
factors associated with accidental (fatal and non-fatal)
PDO, studies that exclusively examine suicide or self-
poisoning were excluded. Further, studies that did not
consider risk markers for overdose were excluded, as were
studies focusing on: infants or children under 12; overdose
after drug treatment; recurrent overdose; or the effects of
an intervention or policy.
Databases, search strategy and criteria
Relevant literature was identified through electronic
searches of databases: Medline OVID (1946–present),
Cochrane Library (1960–present), Cumulative Index to
Nursing and Allied Health Literature (1981–present),
PsycInfo (1967–present), Scopus (1996–present) and ISI
Web of Knowledge (1968–present). Relevant literature
examined included peer-reviewed, published papers, ab-
stracts and papers presented at scientific conferences, as
well as “grey literature”. Grey literature was identified
through manual review of relevant reference lists. Elec-
tronic databases were searched using Medical Subject
Heading keywords for indexed databases (Medline and
PsycInfo) and keywords for indexed and non-indexed
databases. A medical librarian was consulted to review
the databases searched, search terms and search strategy
(Appendix 1).
Study selection
After electronic search, duplicate citations were removed.
Titles of references were reviewed for relevancy to ensure
the article examined PDO. The abstracts of potentially
relevant titles were reviewed to further assess a study’s eli-
gibility for inclusion. If the study abstract was considered
eligible, the full text of the study was retrieved and evalu-
ated to determine if the study was eligible for inclusion.
Two reviewers independently reviewed the full text of
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studies identified for inclusion. In cases of disagreement,
the study was discussed until consensus was reached.
Data extraction
Information about the characteristics of each study was
extracted, and data were extracted to identify the most
commonly studied risk markers, and to calculate the
unadjusted odds ratio of PDO. This was done in two
steps: 1) information on risk markers for PDO was
collected from each study, and 2) a list was generated
to compare which risk markers for PDO were most fre-
quently examined. Risk marker information was catego-
rized into common domains, and risk markers were
consolidated where possible (not shown). If a paper was
deemed eligible for inclusion, but data on the number
of individuals with the outcome or the risk marker of
interest were not extractable, the corresponding author
of the paper was contacted for additional information.
Articles meeting these criteria were selected for qualita-
tive review and characteristics of these studies were
reviewed. Risk markers (sex, age, race, comorbid psy-
chiatric disorder, comorbid SUD and urban/rural of the
area of residence) were selected for the quantitative
analysis when five or more studies examined the same
risk marker.
Quality assessment
After full-text review, the quality of studies eligible for
inclusion was evaluated. Quality of relevant studies identi-
fied through automated search and hand search of refer-
ences was evaluated using the Newcastle–Ottawa Quality
Assessment Scale (Wells et al. 2011). Quality assessments
of cross-sectional studies were evaluated using the
modified Newcastle–Ottawa Quality Assessment Scale
(Herzog et al. 2013).
Data synthesis and analysis
The unadjusted odds ratio measuring the association of
each risk marker with PDO was estimated for each
study. Forest plots were created to show the distribu-
tion of effect estimates across studies for each risk
marker studied. Heterogeneity was assessed using two
statistics – Cochran’s Q test statistic and its corre-
sponding p-value, and I2 statistics. The Q statistic tests
the null hypothesis that each study evaluates the same
effect, whereas the I2 indicates the proportion of total
variation across studies that is due to unexplained het-
erogeneity (Higgins and Thompson 2002). For the Q
statistic, a p-value of ≤0.05 was considered statistically
significant and the effect estimates from the studies
were considered heterogeneous. An I2 above 0.5 is con-
sidered heterogeneous (Higgins and Thompson 2002).
If a heterogeneous result is found, summary effect esti-
mates from a random effects models should be considered
(Riley et al. 2011). For comparison purposes and as a test
of sensitivity of the results to model choice, the results of
both fixed and random effects model are presented in all
forest plots.
When the number of studies permitted, sources of
heterogeneity were investigated by stratification analysis
according to study design, study quality assessment
score, fatal vs combined fatal and nonfatal overdose
outcomes, and whether the study outcome was any
overdose, medication overdose, PDO or prescription
opioid overdose. Heterogeneity was evaluated for each
stratified analysis. “One study removed” sensitivity ana-
lyses were conducted to assess the robustness of the sum-
mary odds ratio. Publication bias was assessed with funnel
plots (not shown) and Rosenthal’s fail-safe N (Persaud
1996). Analyses were conducted in Microsoft Excel 2010
(Microsoft Corporation, Redmond, Washington), Compre-
hensive Meta-Analysis version 2 (Biostat Inc., Englewood,
New Jersey) and SAS version 9.4 (Statistical Analysis Soft-
ware, Cary, North Carolina).
Results
Electronic database searching generated 10,068 refer-
ences of potential relevance. An additional 70 refer-
ences were identified through manual review of the
references of the studies that underwent quality assess-
ment. From the potentially relevant references, 1771
duplicate references were removed, leaving a total of
8367 records to be screened by title, study design and
abstract content. After title review and exclusion of
commentaries, and case reports, 186 references
remained. The full-texts of these references were ac-
quired. After further review, 29 studies were deemed
eligible for the qualitative and quantitative synthesis
(Fig. 1). These 29 studies were evaluated according to
their study design using the Newcastle–Ottawa Quality
Assessment Scale (Tables 1, 2, 3). In this version of the
assessment scale, the best possible assessment scale
score varies by study design, where the highest possible
score for case-control and cross-sectional studies is a
10 and the highest possible score for cohort studies is a
9. A higher score denotes a better quality study. Over-
all, the case-control and cohort studies were of high
quality, with mean assessment scale scores of 9.0/10
and 8.1/9 for case-control and cohort studies respect-
ively. The cross-sectional studies had a mean scale
score of 5.4/10.
Characteristics of included studies
Of the 29 studies included, only three investigated study
populations outside the United States (Tables 4 and 5)
(Gomes et al. 2011; Hulse et al. 2001; Caudarella et al.
2016) and one exclusively examined adolescents (Hulse et
al. 2001). Of the remaining 26 studies, nine considered
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the entire United States, including four being con-
ducted in veterans (Bohnert et al. 2012; Bohnert et al.
2011; Seal et al. 2012; Zedler et al. 2014), and one fo-
cused on women in the general population (Mack
2013). Of the 17 studies conducted in the United States
that focus on smaller geographic areas, two were lo-
cated in New Mexico (Paulozzi et al. 2012; Centers for
Disease Control and Prevention 2005), two were lo-
cated in Utah (Centers for Disease Control Prevention
2005; Lanier et al. 2012), two were located in
Washington State (Dunn et al. 2010; Centers for
Disease Control Prevention 2009), two were located in
West Virginia (Hall et al. 2008; Peirce et al. 2012), while
the others evaluated the Appalachian counties of
Kentucky (Havens et al. 2011a), Los Angeles (Silva et
al. 2013), Boston (Bauer et al. 2016)), New York City
(Silva et al. 2013; Cerdá et al. 2013; Brady et al. 2015),
Colorado (Dilokthornsakul et al. 2016), North Carolina
(Whitmire and Adams 2010), Oklahoma (Piercefield et
al. 2010) and Oregon (Hartung et al. 2007). The time
periods of the studies conducted in Washington State
overlapped by 3 years, but each study contained data
for a time period that did not overlap (Dunn et al.
2010; Centers for Disease Control Prevention 2009).
Similarly, the studies in West Virginia overlap by 1 year,
but one study examines all residents of the state and
unintentional overdose decedents in 1 year (Hall et al.
2008), while the other evaluates residents of the state
who received and filled a prescription for a controlled
substance over a two and half year time period (Peirce
et al. 2012). With the exception of California, Colorado,
North Carolina, New York and Oregon, the majority of
these locations had age-adjusted PDO death rates that
were higher than the national rate (16.3 per 100,000
population) in 2015, the latest year for which data were
available (Rudd 2016; Hartung et al. 2007).
The outcomes evaluated in the 29 studies included
morbidity and mortality measures. Drugs assessed in
these studies were not specifically limited to prescrip-
tion opioids. Ten of these studies focused on prescrip-
tion opioid overdose (Bohnert et al. 2011; Dunn et al.
2010; Lanier et al. 2012; Gomes et al. 2011; Seal et al.
2012; Cerdá et al. 2013; Brady et al. 2015; Dilokthornsa-
kul et al. 2016; Hartung et al. 2007), eight examined
PDO (Centers for Disease Control and Prevention
2011; Coben et al. 2010; Silva et al. 2013; Mack 2013;
Centers for Disease Control and Prevention 2005;
Centers for Disease Control Prevention 2009; Peirce et
al. 2012; Paulozzi et al. 2011), three examined overdose
from both prescription and over-the-counter (OTC)
medications (Bohnert et al. 2012; Hulse et al. 2001;
Piercefield et al. 2010), one examined non-illicit drug
Fig. 1 Flow diagram of the identification, review and selection of included prescription drug overdose meta-analysis articles. Footnote: Adapted
From: (Moher et al. 2009)
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overdose (Centers for Disease Control Prevention 2005)
including prescription drugs, OTC medications, and al-
cohol, and the remaining eight examined unintentional
overdose deaths—with some indication of prescription
drug use (Havens et al. 2011a; Paulozzi et al. 2012; Cau-
darella et al. 2016; Zedler et al. 2014; Hall et al. 2008;
Bauer et al. 2016; Whitmire and Adams 2010; Turner
and Liang 2015). Of the 29 studies, ten (Coben et al.
2010; Dunn et al. 2010; Havens et al. 2011a; Silva et al.
2013; Hulse et al. 2001; Seal et al. 2012; Zedler et al.
2014; Dilokthornsakul et al. 2016; Hartung et al. 2007;
Turner and Liang 2015) examined nonfatal overdose.
One study examined all fatal poisonings and all intents,
including suicide and homicide (Rudd et al. 2016).
Identification of risk markers
Risk marker information was extracted and evaluated for
the most commonly examined variables across the 29
eligible studies: sex, age, white race, psychiatric disorders,
SUDs, and urban/rural residence. Specifically, 21 studies
examined sex, 13 studies examined age as a categorical
variable, 14 studies examined race, 11 studies examined
psychiatric disorders, 10 studies examined SUDs and five
studies examined urban/rural residence.
Synthesis and findings of the quantitative review
Sex
Most studies found that the proportion of males who
overdosed was greater than the proportion of females
Table 2 Newcastle-Ottawa quality assessment scale ratings for the 7 cohort studies included




















1 1 1 1 2 1 1 0 8 (high)
Bohnert et al.
2012
1 1 1 1 2 1 1 0 8 (high)
Caudarella
et al. 2016
1 1 1 1 2 1 1 1 9 (high)
Dunn et al. 2010 1 1 1 1 2 1 1 0 8 (high)
Hartung et al.
2007
1 1 1 1 2 1 1 0 8 (high)
Seal et al. 2012 1 1 1 1 2 1 1 0 8 (high)
Turner and
Liang 2015
1 1 1 1 2 1 1 0 8 (high)
mean 8.1













CDC Medicaid. 2009 1 0 0 1 0 2 1 5 (low)
CDC Non-illicit Drugs
Utah 2005
1 0 0 1 0 2 1 5 (low)
CDC Prescription opioid
pain relievers. 2011
1 0 0 1 1 2 1 6 (low)
CDC Urbanization,
New Mexico, 2005
1 0 0 2 2 2 1 8 (high)
Coben et al. 2010 1 0 0 1 1 2 1 6 (low)
Havens et al. 2011a 1 0 0 1 2 1 1 5 (low)
Hall et al. 2008 1 0 0 1 0 2 1 5 (low)
Hulse et al. 2001 0 0 0 1 0 2 1 4 (low)
Mack 2013 1 0 0 1 0 2 1 5 (low)
Piercefield et al. 2010 1 0 0 1 0 2 1 5 (low)
Rudd et al. 2016 1 0 0 1 1 2 1 6 (low)
Silva et al. 2013 1 0 0 0 2 1 1 5 (low)
mean 5.4
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Table 4 Risk markers and outcomes of studies evaluating prescription drug overdose
First author, year Risk markers and exposures assessed Outcome Sample size
Bauer et al. 2016 Age, sex, race/ethnicity, veteran, location of
death, autopsy performed
Drug overdose death 28,033
Bohnert et al. 2011a Sex, age, race, clinical diagnoses, comorbid
conditions, as well as opioid dose and schedule
Unintentional prescription opioid overdose
(ICD-10 X42, X44, Y12 or Y14 in combination
with T40.2)
155,434
Bohnert et al. 2012a Sex, age, Charlson comorbidities, psychiatric diagnoses,
substance use disorders, alcohol use disorders, other
specific drug use or mental health disorders
Death by accidental medication overdose was an
accidental death with an underlying cause of
death coded as ICD-10 codes X40-X45 due in part
or whole to prescription or over the counter
medications (ICD-10 codes T36.0-T39.9, T40.2-T40.4,
and T42.0-T50.9)
3,291,891
Brady et al. 2015 ED utilization, age, sex, race, clinical characteristics Prescription drug overdose death 5464
Caudarella et al. 2016 Age, gender, ethnicity, homelessness, incarceration,
daily cocaine injection, daily heroin injection, daily
crack smoking, methadone maintenance treatment,
HIV serostatus, and HCV serostatus
Overdose mortality 2317
CDC Medicaid. 2009 Sex, age, Medicaid A Washington state resident whose death certificate
had a manner of death listed as “accidental” or
“natural” and one or more contributing causes coded
as ICD-10 (T40.0-T40.6 and F11) and specific words
compatible with acute drug intoxication recorded
in any death field and a prescription opioid in any




Sex, age, area of residence Non-illicit drug poisoning death 2,281,235
CDC Prescription opioid
pain relievers. 2011
Sex, age, race Prescription drug overdose deaths (with underlying
causes of deaths listed as ICD-10 codes X40-X44,
X60-X64, X85 or Y10-Y14 and having T36-T39, T40.2-T40.4,




Urbanization Unintentional poisoning deaths from prescription drugs
(i.e. methadone, other opioid painkiller, tranquillizer/muscle
relaxant, antidepressant, barbiturate, or other
prescription drug)
17,919,059
Cerdá et al. 2013 Sex, age, race Analgesic overdose fatalities (ICD-10 X40-X44, T40.0-T40.2) 3883
Coben et al. 2010 Sex and age Hospitalizations for poisoning by prescription opioids,
sedatives and tranquilizers (ICD-9965.02, 965.09, 965.5,
965.8, 967.0, 969.4, 969.5, 967.8, and 967.9.) Poisonings
were classifıed as unintentional if there was an E-code
present in the E850–E858 range (accidental poisonings




Sex, age, mean morphine dose equivalents, methadone
use, chronic opioid use, pain diagnosis, comorbidities,
history of other medication use
≥1 medical claim for an emergency department visit or a
hospitalization associated with an opioid overdose
3264
Dunn et al. 2010 Sex, age, history of depression, history of substance
abuse, opioid dose, any opioid use
Opioid-related overdose death, or non-fatal event defined
as definite or probable opioid-related overdose
9940
Gomes et al. 2011c No. of pharmacies dispensing opioids, daily dose of
opioids (>200 mg MME)
Opioid-related death 2212
Hall et al. 2008 Sex, age, marital status and highest education Unintentional drug overdose deaths that involved
prescription pharmaceuticals. This excluded those
overdoses due solely to illicit drugs, over-the-counter
products, or alcohol.
182,170
Hartung et al. 2007 Type of long acting opioid (Methadone, Oxycodone,
Fentanyl, Morphine)
Administrative claims for an opioid-related serious adverse
event, ED encounter or hospitalization for opioid-related
adverse event (CPT code 99281-99285 or 99,288 or ED
revenue center codes of 45× or 981 with ICD-9965.0×),
opioid poisoning (ICD-9965.0×), or overdose symptoms
(ICD-9 codes 780.0×, 78.07×, 418.81, 518.82, 564.0×)
5684
Havens et al. 2011a Sex, age, race, psychiatric comorbidities, substance use Non-fatal overdose 400
Hulse et al. 2001 Sex Hospitalization for prescription /over the counter
drugs
160
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who overdosed. However, there was some variation in ef-
fect estimates by sex across studies. Twelve studies
showed that males were at statistically significant in-
creased risk for PDO (Centers for Disease Control and
Prevention 2011; Coben et al. 2010; Centers for Disease
Control Prevention 2005; Bohnert et al. 2012; Paulozzi
et al. 2012; Lanier et al. 2012; Centers for Disease
Control Prevention 2009; Hall et al. 2008; Bauer et al. 2016;
Brady et al. 2015; Piercefield et al. 2010; Rudd et al. 2016),
six studies showed that there were no statistically significant
differences between sexes (Bohnert et al. 2011; Dunn et al.
2010; Havens et al. 2011a; Silva et al. 2013; Caudarella et al.
2016; Zedler et al. 2014) and three studies showed that fe-
males were at increased risk for PDO (Hulse et al. 2001;
Cerdá et al. 2013; Turner and Liang 2015). Overall, the ran-
dom effects model showed a statistically significant in-
creased risk for males as compared to females (summary
odds ratio (SOR) = 1.33, 95% confidence interval (CI) 1.17,
1.51) (Fig. 2). The results of the “one study removed” ana-
lysis indicated that the SOR was robust, as SOR from ran-
dom effects models ranged from 1.29 to 1.38. Rosenthal’s
classic fail safe N, the number of new, unpublished, or null
studies that would be needed to make the overall finding
not significant, was 2313 (Persaud 1996).
Age
The variation in the effect estimates across studies com-
paring <25, 35-44, 45-54, and ≥55 years to 25-34 years
(reference group) showed that the 35-44 and 44-54 year
age groups were most often at the greatest risk for over-
dose (Figs. 3 and 4). All studies included in Figs. 3 and 4
examined fatal overdoses. For the study conducted
in Washington State (Centers for Disease Control
Prevention 2009), both the Medicaid population and
the total population distribution of overdoses were
examined, even though the age distribution of overdose
was similar in the total population and the Medicaid
population.
Race
Of the 14 studies that examined race as a risk marker, 11
showed that Whites were at increased risk for PDO as
compared to all other racial groups combined (Fig. 5). The
overall SOR showed that Whites had statistically signifi-
cant increased risk for PDO when compared to other ra-
cial groups combined (SOR 2.28, 95% CI 1.93, 2.70).
Results of the “one study removed analysis” showed SOR
from random effects models ranging from 2.13 to 2.42.
Rosenthal’s classic fail safe N was 3785 (Persaud 1996).
Table 4 Risk markers and outcomes of studies evaluating prescription drug overdose (Continued)
Lanier et al. 2012 Sex, age, race, marital status, body mass index,
uninsured, education, employment status, smoking
status, residence in an urban county, military service
Death from prescription opioids 1562
Mack 2013 Age and race Prescription drug overdose deaths (with underlying
causes of deaths listed as ICD-10 codes X40-X44, X60-X64,
X85 or Y10-Y14 and having T36-T39, T40.2-T40.4, T41-T43.5,
and T43.8-T50.8) as contributing causes
157,237,928
Paulozzi et al. 2012 Sex, age, prescription history Death from unintentional drug overdose 6293
Peirce et al. 2012 Prior doctor and or pharmacy shopping Controlled substance-related death 1,049,903
Piercefield et al. 2010d Sex, age, race and urban/rural Medication overdose deaths 3,540,517
Rudd et al. 2016 Sex, age, race Prescription drug overdose deaths (with underlying
causes of deaths listed as ICD-10 codes X40-X44,
X60-X64, X85 or Y10-Y14 and having T36-T39, T40.2-T40.4,
T41-T43.5, and T43.7-T50.8) as contributing causes
641,538,924
Seal et al. 2012a Opioid use, post-traumatic stress disorder (PTSD),
PTSD with or without other mental health disorders
Opioid-related accidents and overdoses (ICD-9 codes:
965.00, 965.01, 965.02,965.09, E850.0, E850.1, E850.2,
E935.0, E935.1, and E935.2)
141,030
Silva et al. 2013 Sex, race, psychiatric care, substance use Non-fatal overdose on prescription opioids and/or
tranquilizers
596
Turner and Liang 2015 Sex, age, US region, clinical conditions, mental health
and substance use disorders,
Any drug overdose event 206,869
Whitmire and Adams
2010d
Eligibility category, race, residence, specific disorders,
drug claims
Unintentional overdose death (ICD-10 X40-X49) 2801
Zedler et al. 2014 Age, sex, race/ethnicity, marital status, BMI, US Census
region, comorbidities, opioid use, all-cause health care
utilization (ED visits)
Occurrence of serious opioid-related toxicity or overdose
as defined by listed ICD-9-CM and CPT codes
8987
MMEs morphine milligram equivalents, CPT current procedural terminology, ICD-9 international classification of diseases, 9th revision, ICD-10 international
classification of diseases, 10th revision, CS controlled substances, OME office of the medical examiner
aStudies are not independent
bInformation refers to deaths occurring between 1999 and 2003
cInformation refers to deaths occurring between 2004 and 2006
dMatching variables not included in risk markers
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Psychiatric disorders
In each of the 11 studies that examined psychiatric disor-
ders, the incidence of drug overdose in individuals with
psychiatric disorders was higher than in individuals with-
out psychiatric disorders (Tables 6 and 7). However, these
studies used varying definitions of conditions considered
to be psychiatric disorders. The overall SOR showed that
individuals with psychiatric disorders have a statistically
significant increased risk for PDO compared with those
who do not have psychiatric disorders (SOR = 3.94, 95%
CI 3.09, 5.01). The results of the “one study removed
analysis” showed SOR from random effects models
ranging from 3.60 to 4.11. Rosenthal’s classic fail safe
N was 7396.
SUDs
SUDs were found to be associated with an increased
risk of PDO in each of the 10 studies that examined
this risk marker. Although the definition of SUDs used
in these studies varied, the results were generally con-
sistent (Fig. 6). Overall, the SOR of PDO associated
with SUDs was 5.24 (95% CI 3.53, 7.76). The results of
the “one study removed analysis” showed that random
effects SORs ranged from 4.53 to 5.92. Rosenthal’s clas-
sic fail safe N was 9465.
Rural residence
The five studies that examined the association rural/
urban residence with the risk of PDO reported conflict-
ing results. The estimated ORs of PDO associated with
rural areas compared to urban areas varied consider-
ably across studies (Fig. 7). The random effects SOR of
PDO associated with rural residence was not statisti-
cally significant (SOR = 0.93, 95% CI 0.72, 1.19).
Heterogeneity
Heterogeneity in effect estimates was assessed with the
Q and I2 statistics and was found to be significant for
each of the six risk markers examined (Figs. 2, 3, 5, 6, 7
and 8). Heterogeneity in effect estimates persisted across
each of the six risk markers examined when stratifying
by study design, quality assessment score, type of sub-
stances used, and whether the study examined fatal over-
dose or fatal and non-fatal overdose (not shown).
Discussion
Given the current drug overdose crisis in the United
States, it is important to understand risk markers for PDO
and understand how findings may vary across studies.
This meta-analysis summarizes published literature on
PDO for six risk markers that were most frequently
assessed in the literature: male sex, age 35-44 years, white
race, comorbid psychiatric disorder diagnosis, comorbid
diagnosis of a SUD and urban/rural area of residence.
While, none of the risk markers identified in this system-
atic review are easily modifiable, understanding them may
help identify individuals at heightened risk for PDO.
While males are at greater risk for PDO on average,
sex is a relatively weak and inconsistent risk marker –
resulting in an overall 20% increase in PDO in men. Six
Fig. 2 Forest plot, summary odds ratio and 95% confidence of prescription drug overdose with sex. The size of each square is proportional to the
relative weight that each study contributed to the summary odds ratio. The summary odds ratio is indicated by the diamond. Horizontal bars indicate
the 95% confidence interval. Heterogeneity: Q statistic: 553.2, df = 21, P < 0.0001. I2 = 96.2. Footnote: The Bohnert et al. (2011) and Bohnert et al. (2012)
papers arose from the same underlying population. In the CDC Medicaid 2009 study, the Medicaid population is a subgroup of the total population.
Note: The standard errors for the CDC Prescription opioid pain relievers 2011 and Rudd et al. (2016) studies may be smaller than what was used to
calculate the confidence intervals. The sample size for this study exceeded the maximum allowed by Comprehensive Meta-Analysis software, so one
digit was removed from each component of the odds ratio
Brady et al. Injury Epidemiology  (2017) 4:24 Page 13 of 24
studies did not find any increase in risk for PDO for
males as compared to females (Bohnert et al. 2011;
Dunn et al. 2010; Havens et al. 2011a; Silva et al. 2013;
Caudarella et al. 2016; Zedler et al. 2014). Three studies
found the females were at increased risk for PDO,
which may be a consequence of the study populations
examined in these two studies (Hulse et al. 2001; Cerdá
et al. 2013; Turner and Liang 2015). First, Cerdá et al.
(2013) found that in comparison to females, males in
New York City appear to be at greater risk for other ac-
cidental death relative to opioid analgesic PDO. The
study’s finding of increased risk for unintentional opioid
analgesic PDO in women in New York City may be
related to the authors’ choice of reference group (non-
overdose-related fatal accidents). It is known that
overall in the United States males are at greater risk for
accidental death than women (Waldron et al. 2005). Thus,
men in the reference group have a lower risk of fatal over-
dose than the general population as well as those experi-
encing non-accidental death, resulting in higher estimates
of gender differences (Sorenson 2011; Insurance Institute
for Highway Safety 2017). Second, Hulse et al. (2001)
studied a small group of adolescents seeking treat-
ment in the ED for alcohol or drug related ailments
and found females have a greater risk for non-fatal
prescription drug related overdose in comparison to
males. The Hulse et al. finding is consistent with
literature on rates of hospitalization and ED visits for
prescription drug use and non-fatal poisoning which
show women are more likely than men to utilize care for
Fig. 4 Line graph of summary odds ratios of prescription drug
overdose associated with age. Error bars indicate the 95%
confidence interval. <25 years vs. 25-34 years
Fig. 3 Forest plot, summary odds ratio and 95% confidence of prescription drug overdose with age. For all plots, 25-34 years is the reference
group. The size of each square is proportional to the relative weight that each study contributed to the summary odds ratio. The summary odds
ratio is indicated by the diamond. Horizontal bars indicate the 95% confidence interval. <25 years vs. 25-34 years Heterogeneity: Q statistic: 407.8,
df = 13, P < 0.0001. I2 = 96.8; 35-44 years vs. 25-34 years Heterogeneity: Q statistic: 172.0, df = 13, P < 0.0001. I2 = 92.4; 45-54 years vs. 25-34 years
Heterogeneity: Q statistic: 213.0, df = 13, P < 0.0001. I2 = 93.9; ≥55 years vs. 25-34 years Heterogeneity: Q statistic: 440.0, df = 13, P < 0.0001.
I2 = 97.0. Footnote: The standard errors for the CDC Prescription opioid pain relievers 2011, Mack (2013) and Rudd et al. (2016) studies may be
smaller than what was used to calculate the confidence intervals. The sample size for this study exceeded the maximum allowed by Comprehensive
Meta-Analysis software, so one digit was removed from each component of the odds ratio
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prescription drug misuse or non-fatal poisoning (Cai et al.
2010; Unick et al. 2013; Xiang et al. 2012). Finally, Turner
et al. studied HMO beneficiaries and note that they may
miss deaths occurring out of network or outpatient
deaths. Women in the United States are more health-
seeking than men and hospitalization for PDO is higher
for women than for men, which may explain the increased
risk for PDO in women compared to men observed in
this study (Coben et al. 2010; Turner and Liang
2015).
Understanding the relationship between age and PDO
is complicated by the fact that many studies examine
different age categories. Increased risk for overdose is
highest in the 35-44 age group, which in part may result
from a cohort effect arising from the aging baby-boomer
generation (Miech et al. 2011). However, this review
did not specifically assess birth cohort as a risk marker.
Additionally, age and physical condition affect one’s
ability to metabolize drugs (Smith 2009). Several studies
have posited on the negative long-term implications of
nonmedical use of prescription drugs in adolescents and
young adults, including greater risk for dependence
and bearing children dependent on prescription drugs
(Whiteside et al. 2013; Patrick et al. 2012; Compton
and Volkow 2006a, 2006b).
Whites have higher fatal and non-fatal PDO rates than
other races. While the other studies included in this
meta-analysis evaluated risk for fatal PDO, the only
study that did not find that Whites were at increased
risk for overdose evaluated self-reported nonfatal
overdose incidents (Havens et al. 2011a). This study of
nonfatal overdose incidents (Havens et al. 2011a) also
used respondent-driven sampling – a method for
sampling hard-to-reach populations – which may have
resulted in a sample that is more homogeneous than
would be obtained with traditional sampling methods
(Havens et al. 2011a; Heckathorn 1997). Other studies
have found that White race is associated with an
increased risk for alcohol dependence, and heroin
(Hasin et al. 2007; Woerle et al. 2007; Calcaterra et al.
2013). There are other reasons why non-Whites may
be at lower risk for overdose related to differences in
treatment for pain in White and non-White patients.
It has been found that Black patients are less likely to
be assessed and treated for pain than White patients
(Hoffman et al. 2016). In survey respondents, this
under-treatment for pain in Black patients has been
linked to inaccurate beliefs among medical students
and residents that Blacks patients experience less pain
than White patients due to false assumptions about
biological differences (Hoffman et al. 2016). Even
when assessed for pain and being prescribed pain
medication, surveys of pharmacies in New York City
indicate that pharmacies in non-White neighborhoods
were less likely to stock prescription opioid medications
than pharmacies in White neighborhoods (Green et al.
2005; Singhal et al. 2016; Morrison et al. 2000). Decreased
access to and availability of prescription opioids to
non-White patients in comparison to White patients
may translate to less prescription opioid use and less
risk of PDO.
Across studies, this review found that patients with
psychiatric disorders were at increased risk of PDO.
There are many reasons that patients with psychiatric
disorders are at increased risk for PDO. First, patients
with psychiatric disorders are often prescribed
Fig. 5 Forest plot, summary odds ratio and 95% confidence of prescription drug overdose with white race. The size of each square is
proportional to the relative weight that each study contributed to the summary odds ratio. The summary odds ratio is indicated by the diamond.
Horizontal bars indicate the 95% confidence interval. Heterogeneity: Q statistic: 144.2, df = 13, P < 0.0001. I2 = 91.0. Footnote: The standard errors
for the CDC Prescription opioid pain relievers 2011, Mack (2013) and Rudd et al. (2016) studies may be smaller than what was used to calculate
the confidence intervals. The sample sizes for these studies exceeded the maximum allowed by Comprehensive Meta-Analysis software, so one
digit was removed from each component of the odds ratios
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medication to treat their illness and these medications,
(e.g. benzodiazepines, anti-depressants, barbiturates)
interact with opioids to increase the risk of fatal and
non-fatal overdose (Jones et al. 2012; Maurer and Bart-
kowski 1993; U.S. Food and Drug Administration 2016).
Patients with psychiatric disorder may also self-medicate
with alcohol, which combined with opioids, can also
increase the risk of fatal or non-fatal overdose (Gudin et
al. 2013). Additionally, psychiatric and substance use dis-
orders often co-occur (Mueser et al. 1998; Nunes and
Levin 2004). While all studies examined found increased
risk for PDO, there was significant heterogeneity in the
effect estimates across studies. The heterogeneity in the
psychiatric disorder meta-analysis results may stem from
Fig. 6 Forest plot, summary odds ratio and 95% confidence of prescription drug overdose with psychiatric disorders. The size of each square is
proportional to the relative weight that each study contributed to the summary odds ratio. The summary odds ratio is indicated by the diamond.
Horizontal bars indicate the 95% confidence interval. Heterogeneity: Q statistic: 191.2, df = 10, P < 0.0001. I2 = 94.8. Footnote: PD- Psychiatric Disorders
(Definitions for each study are listed in Appendix 2). The Bohnert et al. (2011), Bohnert et al. (2012) and Seal et al. 2012 papers arose from the same
underlying population
Table 7 Risk markers for prescription drug overdose stratified by study characteristics
Age < 25 Age 35-44 Age 45-54 Age 55 and older
N Random
effects
95% CI N Random
effects
95% CI N Random
effects
95% CI N Random
effects
95% CI
Unadjusted OR 14 0.27 0.20, 0.37 14 1.52 1.31, 1.76 14 1.38 1.18, 1.61 14 0.37 0.29, 0.48
Outcome definition
Fatal overdose - - - - - - - - - - - -
Fatal and nonfatal overdose - - - - - - - - - - - -
Study Design
Case control 5 0.60 0.43, 0.83 5 1.54 1.26, 1.88 5 1.26 0.90, 1.76 5 0.30 0.12, 0.72
Cohort 1 0.34 0.21, 0.55 1 2.54 2.20, 2.93 1 1.83 1.60, 2.11 1 0.19 0.16, 0.22
Cross-sectional 8 0.17 0.14, 0.21 8 1.41 1.22, 1.64 8 1.39 1.12, 1.72 8 0.47 0.38, 0.58
Quality Assessment Score
High (7-10) 5 0.56 0.38, 0.81 5 1.78 1.35, 2.33 5 1.33 0.98, 1.80 5 0.24 0.11, 0.55
Low (0-6) 9 0.18 0.15, 0.23 9 1.39 1.21, 1.61 9 1.40 1.14, 1.71 9 0.47 0.39, 0.58
Study Outcome
Medication overdose 6 0.22 0.17, 0.27 6 1.57 1.23, 1.99 6 1.67 1.47, 1.90 6 0.35 0.20, 0.61
Prescription opioid overdose 6 0.34 0.14, 0.83 6 1.64 1.40, 1.93 6 1.25 0.85, 1.83 6 0.42 0.26, 0.68
Overdose of any substance 2 0.25 0.12, 0.51 2 1.09 1.03, 1.16 2 1.09 0.76, 1.56 2 0.28 0.07, 1.11
Exclusions
Bohnert et al. 2011 and Paulozzi et al. 12 0.23 0.17, 0.32 12 1.53 1.30, 1.79 12 1.48 1.26, 1.73 12 0.44 0.35, 0.57
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the fact that each of these risk markers is a general
categorization that groups multiple psychiatric disorders
when in fact, certain psychiatric disorders, such as anx-
iety disorders or depressive disorders, may have greater
risk for PDO than other psychiatric disorders (Seal et al.
2012). Further, the prevalence of specific psychiatric dis-
orders may differ from study to study, leading to varied
effect estimates. Similarly, the prevalence of risk for spe-
cific psychiatric disorders among these populations e.g.
populations that experience more stressors, such as vet-
erans, may be at greater risk for PDO than the general
population, may contribute to heterogeneity. Addition-
ally, heterogeneity in the study ORs may result from lack
of specificity in the study outcome. One study, Seal et al.
(2012), examines the effect of having any psychiatric dis-
order inclusive of SUDs, which likely results in a greater
odds ratio when compared with the other studies which
do not include SUDs in their definition of psychiatric
disorders. Seal et al. also examines prescription opioid-
related accidents. Many more people suffer from opioid-
related adverse events (e.g. constipation, malaise, fatigue,
lethargy, respiratory failure, non-fatal opioid poisoning)
and opioid-related accidents than die from prescription
opioid-related intoxication (Seal et al. 2012; Hartung et
al. 2007). Additionally, Seal et al. restrict their analysis to
veterans experiencing serious non-cancer pain and thus,
the findings of this study might not be generalizable to
veterans experiencing cancer-related pain or non-
veterans (Bohnert et al. 2011; Seal et al. 2012). Bohnert
et al. (2011) found that risk for opioid overdose death
was greater for veterans with cancer-related pain than
for veterans with non-cancer related pain. These pos-
sible explanations highlight the fact that crude study
odds ratios included in the meta-analysis may differ in
the degree to which they are affected by confounding
and effect measure modification.
The heterogeneity in the SUDs finding likely stems
from the different definitions of a SUD in these
studies. The two studies with lower odds ratios used
atypical definitions of SUDs (Dunn et al. 2010; Ha-
vens et al. 2011a). In Dunn et al. (2010), the definition of
SUD is “substance abuse”. In the 2013, Diagnostic and
Fig. 8 Forest plot, summary odds ratio and 95% confidence of prescription drug overdose with rural residence. The size of each square is proportional
to the relative weight that each study contributed to the summary odds ratio. The summary odds ratio is indicated by the diamond. Horizontal bars
indicate the 95% confidence interval. Heterogeneity: Q statistic: 34.5 P < 0.0001. I2 = 88.4. Footnote: Definition 1: Counties in metropolitan areas are
considered urban and the remaining counties of residence were categorized as rural
Fig. 7 Forest plot, summary odds ratio and 95% confidence of prescription drug overdose with SUDs. The size of each square is proportional to the
relative weight that each study contributed to the summary odds ratio. The summary odds ratio is indicated by the diamond. Horizontal bars indicate
the 95% confidence interval. Heterogeneity: Q statistic: 391.9, df = 9, P < 0.0001. I2 = 97.7. Footnote: SUD – Substance Use Disorder (Definitions for
each study are listed in Appendix 2). The Bohnert et al. (2011) and Bohnert et al. (2012) papers arose from the same underlying population
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Statistical Manual of Mental Health Disorders, the diag-
nostic terms “substance abuse” and “substance depend-
ence” were replaced in favor of “SUD.” It may be that
individuals categorized as having “substance abuse” had
less risk of PDO than people who would be categorized as
having an “SUD.” The Havens et al. (2011a) study is cross-
sectional and examined non-fatal overdose in rural drug
users. It did not examine SUDs per se, but rather “ever go-
ing to drug treatment” (Havens et al. 2011a). Given that
this study examined a rural area and that there is a lack of
basic substance abuse treatment services in rural areas
and drug treatment services are underutilized in rural
areas, it is likely that drug treatment utilization would not
be prevalent. Operationalizing “Ever going to drug treat-
ment” as a diagnosis of an “SUD” may be a poor proxy in
a rural setting.
The findings regarding urban/rural as a risk marker
are mixed. The largest increases in PDO death rates
have occurred in rural areas with rates of PDO deaths
in rural areas reaching and sometimes exceeding those
in urban areas (Paulozzi and Xi 2008; Park and Bloch
2016). Rossen et al. (2013) found that drug poisoning
death rates in rural areas in the United States increased
nearly 400% from 1999 to 2009, while death rates in
urban areas in the United States increased almost 280%
from 1999 to 2009. Drug poisoning trends increased
more steeply in rural areas because the age-adjusted
poisoning death rates were much lower in rural areas at
the start of the time period (Rossen et al. 2013). Not-
ably, the highest drug poisoning death rates were found
in central metropolitan areas (Rossen et al. 2013). Thus,
there is an interaction between urban/rural location
and time. An alternative explanation for the heterogen-
eity in the effect estimates of urban/rural status on
PDO may stem from the wide variation in the defini-
tions of “urban” and “rural” used across studies. There
is no one accepted definition of “urban” and “rural”.
Some studies used micropolitan and metropolitan areas
to define urban (Centers for Disease Control Preven-
tion 2005; Centers for Disease Control and Prevention
2005); others identified “urban” and “rural” counties
according to varying thresholds of population density
(Lanier et al. 2012; Piercefield et al. 2010), and one
study used county accountability regions (Appendix 2)
(Whitmire and Adams 2010). These varying defini-
tions may mean that areas of varying urbanicity and
rurality are being grouped together and compared,
which would result in an attenuation of the effect of
urban/rural on PDO.
Several studies have reported that the epidemics of PDO
and nonmedical prescription drug use have not been con-
centrated in metropolitan areas (Wunsch et al. 2009; Pau-
lozzi and Xi 2008; Centers for Disease Control and
Prevention 2005; Havens et al. 2011b; Wang et al. 2013).
This is noteworthy because previous research on drug use
and drug overdose epidemics has focused on urban areas
(Coffin et al. 2003; Hembree et al. 2005). Research aimed
at understanding differences in urban/rural prescription
drug use is scant. To help appreciate why there are urban/
rural differences in nonmedical opioid use, Keyes et al.
(2014) conceptualized several reasons why individuals res-
iding in rural counties may be vulnerable to nonmedical
prescription drug use and abuse. Keyes et al. hypothe-
sized that increased sales of opioids in rural areas led to
greater availability for nonmedical use of prescription
opioids and that close-knit kinship and social networks
allowed for faster dispersion of prescription opioids for
those at risk. Further, Keyes et al. (2014) posit that in-
creasing economic hardship and unemployment and
out-migration of upwardly mobile young adults create
environmental stressors that contribute to risk for drug
abuse. Cicero and colleagues (2007) found that in areas
where there was more therapeutic use of prescription
opioids there was also more prescription opioid abuse.
Wang and colleagues examined factors associated with
nonmedical prescription opioid use, and found that
correlates of nonmedical prescription opioid use were
similar for urban and rural areas (Higgins et al. 2003).
Other geographical constructs, such as region or state,
may interact with the urban/rural context. Regional and
local prescribing patterns and availability of other drugs
may affect PDO risk.
Strengths and limitations
This systematic review uses standard meta-analysis guide-
lines to quantitatively assess risk markers for PDO. The
findings may aid clinicians in identifying patients at
heightened risk for PDO. This review is also comprehen-
sive because it covers studies conducted over several de-
cades and in different population groups.
Results from this meta-analysis should be interpreted
with caution. First, the studies reviewed did not focus
exclusively on PDO or PDO death. This review includes
studies that examined non-fatal overdose (Coben et al.
2010; Havens et al. 2011a); PDO as defined in this
study may be related to combining prescription and
illicit drug use (Paulozzi et al. 2012) and may include
PDO of intentional and underdetermined intent
(Rudd et al. 2016). The inclusion of these studies
decreases the specificity of the outcome measure-
ment. However, non-fatal overdose is understudied.
Examining non-fatal overdose is important because
these incidents are near misses and can help researchers
understand more about the rarer occurrence of overdose
death. Further, it is not always clear-cut what should be
categorized as PDO and if it should be separated from
overdose overall.
Brady et al. Injury Epidemiology  (2017) 4:24 Page 19 of 24
Second, this review presents SOR from the random ef-
fects model in the presence of unexplained heterogeneity
for each of the six risk markers. Some researchers favor
not presenting a SOR in the presence of a large amount
of unexplained heterogeneity since summary measures
generated from random effects models are not always
more conservative than summary measures of fixed ef-
fect estimates (Higgins et al. 2003; Higgins and Green
2011). Additionally, large unexplained heterogeneity sug-
gests that studies may be evaluating different effects or
compounding biases (Higgins et al. 2003; Higgins and
Green 2011). While unexplained heterogeneity is not
uncommon in meta-analyses of observational studies, it
means that less emphasis should be placed on the SOR.
Further, this heterogeneity may stem for factors that
were not able to be controlled for in this study, such as
changing in tolerance to opioids or mixing of different
drugs including prescription opioids, heroin or illegal
manufactured fentanyl.
Third, this meta-analysis did not include several im-
portant risk markers because the number of studies
examining these risk markers was too small. Paulozzi
et al. (2012), Lanier et al. (2012) and Hartung et al.
(2007) reported that type of opioid was strongly asso-
ciated with PDO death. Type of drug, dose, potency
of opioid and duration action, and polysubstance use
are all related to risk of PDO (Paulozzi et al. 2012;
Peirce et al. 2012; Volkow and Thomas 2016).
Additionally, frequent ED utilization and doctor
shopping are found to be extremely predictive of
subsequent PDO death and their associations with
PDO are much stronger than with the risk markers
examined in this review (Peirce et al. 2012; Brady et
al. 2015). Future systematic reviews may update the
present meta-analysis when more epidemiologic
evidence has accumulated for emerging risk markers,
such as type of drug, dose, potency of opioid, duration
of action, polysubstance use, ED utilization and other
healthcare utilization.
Finally, the literature included in this review
spanned a long period of time. It is likely that risk
markers and the strength of their association may
change over time. For instance, geospatial risk for
PDO may change with drug availability and imple-
mentation of laws to prevent diversion. Additionally,
during parts of the study period, changes in the
availability of drugs and opioids may lead to changes
in associated risk markers. Spikes in PDO deaths
have been associated with long-acting opioids, such
as methadone at certain times and other times,
potent legally and illegally produced opioids, such as
fentanyl have been related to increases in PDO
deaths (Rudd 2016; Dunn et al. 2010; Paulozzi et al.
2012; Lanier et al. 2012).
Conclusions
This meta-analysis assesses six risk markers for PDO that
were commonly examined across studies of drug over-
dose: sex, age, race, comorbid psychiatric disorders, SUDs
and area of residence. It reveals that SUD is the risk
marker most strongly associated with PDO, followed by
psychiatric disorders, white race, age 35-44 years and male
sex. Rural residence does not appear to be significantly as-
sociated with PDO. Future research on PDO can address
gaps in the literature, such as the underlying reasons for
prescription drug use, and understanding the comorbidi-
ties and health utilization patterns to help identify individ-
uals at greatest risk for PDO. Findings of this review may
aid clinicians in risk assessment while prescribing opioid
analgesics and inform policymakers to more effectively
allocate resources for intervention programs.
Appendix 1
Search strategy
Medical Subject Headings (MeSH) for Medline OVID:
1) explode prescription drugs/ and explode drug
overdose/;
2) explode prescription drugs/ and explode Poison
Control Centers/;
3) (explode prescription drugs/ or explode Prescription
Drug Misuse/ and explode Opioid-Related Disorders/
or explode Substance-Related Disorders/ or
substance-related disorders/ or amphetamine-related
disorders/ or drug overdose/ or neonatal abstinence
syndrome/ or opioid-related disorders/ or psychoses,
substance-induced/ or substance withdrawal
syndrome/ or “phenomena and processes
(non-MeSH)”/) and (explode Analgesics/ or explode
Prescription Drug Misuse/ and explode Analgesics/ or
explode Controlled Substances/).
MeSH for PsycInfo:
1) explode Prescription Drugs/ or explode Analgesic
Drugs/ or explode opiates/ and explode Drug
Overdoses/or explode Drug Abuse/ or explode Drug
Dependency/.
The automated search used the following search
strategy for indexed and non-indexed databases:
(overdose or substance misuse or drug-related death or
addiction disorder) or (non-fatal overdose or prescrip-
tion drug misuse) or (opioid-related death or (opioids
and mortality) or drug poisoning) and (chronic pain or
chronic pain patients or opioid therapy or opioid
analgesic or prescription pain reliever or controlled
substances or prescription drug).
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Appendix 2
Table 8 Definitions for psychiatric disorder and substance use disorder by study
Risk marker definition
First author, Year Psychiatric Disorder (PD) Substance Use Disorder (SUD) Rural/Urban
Bohnert et al.
2011a
Non-substance use psychiatric disorders Any SUD including alcohol N/A
Bohnert et al.
2012a
Bipolar I or II disorders, Any depressive
disorder, Post-traumatic stress disorder,
other anxiety disorder, and schizophrenia
Any SUD including alcohol N/A







N/A N/A Davis, Weber and Salt Lake City and Utah
counties were categorized as urban and
the remaining counties were categories
were categorized as rural
CDC Urbanization,
New Mexico, 2005b
N/A N/A Definition 1: Counties in metropolitan areas
are considered urban and the remaining
counties of residence were categorized as rural
Definition 2: Counties in metropolitan or
micrpolitan areas are considered urban and the




“Other psychiatric illness” (includes depression,
bipolar/mixed mania, schizophrenia, anxiety/
panic/obsessive compulsive, personality disorder,




Dunn et al. 2010 Depression diagnosis Substance abuse diagnosis two
years prior to entry in the cohort
N/A
Havens et al. 2011a Major depressive disorder, generalized anxiety
disorder, post-traumatic stress disorder, or
antisocial personality disorder
Ever in drug treatment N/A
Lanier et al. 2012 N/A N/A The Utah Department of Health considers an
urban county to have a population density
exceeded 100 persons per sq. mile. Using this
classification, only four counties in the state




N/A N/A County of residence was considered urban if the
county population exceeded 500 persons per sq.
mile of land area, with the remainder termed rural
counties. Two counties: Oklahoma and Tulsa were
categorized as “urban”.
Seal et al. 2012 Mental health diagnoses (ICD-CM-9 codes 290-319:
including depressive disorders, anxiety disorders,
alcohol use disorders, drug use disorders) and
post-traumatic stress disorder
N/A N/A
Silva et al. 2013 Care in a psychiatric hospital Ever in drug treatment N/A
Turner and Liang
2015





“Mental disorders” excluding drug dependence Drug dependence Rural/urban classification variable was created based
on the North Carolina accountability regions. The
ten counties that were a part of the accountability
regions and used to define the “urban” classification
are: Buncombe, Cumberland, Davidson, Durham,
Forsyth, Gaston, Guilford, Mecklenburg, Onslow, and
Wake counties.




aNot independent study populations overlap by 2 years
bMetro and micropolitan area definitions: https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/historical-delineation-
files.html
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